Active ingredient Capreomycin interacts in the following cases:
The safety of capreomycin for use during pregnancy has not been established. Capreomycin has been shown to be teratogenic in rats when given at 3.5 times the human dose. There are no adequate and well controlled studies in pregnant women. Capreomycin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether capreomycin is excreted in human milk. Caution should be exercised when administering to a nursing woman.
Studies have not been performed to determine potential for carcinogenicity, mutagenicity, or impairment of fertility.